•
Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality’s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program.…
•
The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality oversight and supply security of drugs related to COVID-19 prevention and control. The guidelines focus on ensuring the quality and legal supply of common drugs listed in the “Guidelines for Home Treatment of COVID-19 Infected…
•
The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal cardiopulmonary support auxiliary equipment and disposable membrane oxygenator bag for emergency use. The combination is designed for adult patients with acute respiratory failure or acute cardiopulmonary failure, whose symptoms are difficult to control with other…
•
EOC Pharma, a biotech company operating in the US and China, has announced that its New Drug Application (NDA) filing for entinostat has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced…
•
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds, raising a total of USD 107 million. The financing was led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital, with participation from Yuexiu Fund and Yuthai Fund. The proceeds will…
•
US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced a three-year strategic collaboration aimed at advancing scientific research and development in neuroscience and specialized immunology. This academic partnership marks Biogen’s first collaboration in China, highlighting the company’s commitment to expanding its research footprint in…
•
The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have released the “Integrated Pain Management Pilot Work Plan,” aimed at enhancing pain management capabilities in hospitals across China. The plan outlines a pilot program to be implemented from 2022 to 2025, focusing on exploring and…
•
Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with India-headquartered Natco Pharma Limited to become its distribution agent for certain drugs in mainland China. The collaboration aims to address domestic demand for influenza drugs, cancer therapies, and rare disease treatments. The two companies will…
•
China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and translation center” in collaboration with the Shanghai Institute of Nutrition and Health (SINH), CAS. This initiative marks a comprehensive upgrade to their existing strategic partnership. Financial details of the collaboration were not disclosed. Background and…
•
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to secure exclusive global rights to a novel, second – generation gene therapy for spinal muscular atrophy (SMA) from UMass Chan Medical School in the United States. The deal includes all development, manufacturing, and commercialization rights…
•
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received clinical trial approval in China for TST003, its potential first – in – class monoclonal antibody (mAb) targeting Gremlin1. The drug candidate has already received IND clearance from the US FDA in September this year,…
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA) has approved a supplementary Biologic License Application (sBLA) for its biosimilar Hanbeitai (bevacizumab). The approval expands the indications for which Hanbeitai can be used, now including cervical cancer, epithelial ovarian cancer, fallopian tube cancer, and…
•
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio – pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private…
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in the ESLIM – 01 study, a pivotal Phase III trial assessing the efficacy and safety of sovleplenib in treating adult patients with primary immune thrombocytopenia (ITP) in China. This marks a significant milestone in…
•
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II study of its antibody – drug conjugate (ADC) candidate RC48 (disitamab vedotin). The study will assess the efficacy and safety of RC48…
•
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced a partnership agreement with compatriot firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration aims to enhance the research and development (R&D) and manufacturing capabilities of both companies through strategic alignment. Details of the…
•
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ) has entered into an exclusive commercial cooperation agreement with compatriot firm Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. Under the terms of the agreement, CTTQ will be responsible for…
•
Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners,…
•
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for the next two years and beyond as it progresses toward becoming a fully – integrated biopharmaceutical company. The company aims to develop capabilities across the full biotechnology value chain, including in – house discovery, in…
•
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of Dr. Rafael G. Amado as President and Global Head of Cancer Research and Development (R&D), effective December 30, 2022. Dr. Amado will join the company’s management committee as a core member, reporting directly to Dr.…